인플루엔자 백신 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of influenza vaccine Market

The global influenza vaccine market is witnessing strong and sustained growth, driven by increasing seasonal outbreaks, rising government immunization programs, and continuous advancements in vaccine technologies. According to industry estimates, the market was valued at USD 9.2 billion in 2025 and is projected to reach USD 9.96 billion in 2026, ultimately expanding to USD 22.49 billion by 2034, registering a CAGR of 10.72% during 2026-2034.

Market Size and Value Overview

The steady rise in market value reflects the growing global emphasis on preventive healthcare and vaccination coverage. Influenza continues to cause significant global health burdens, with the World Health Organization (WHO) reporting approximately 3 to 5 million severe influenza cases annually, leading to 290,000 to 650,000 deaths worldwide. This increasing disease burden has directly influenced vaccine demand across both developed and developing economies.

In 2025, North America dominated the global market with a value of USD 4.95 billion, accounting for 53.79% of the total global share. The region is expected to maintain strong growth due to advanced healthcare infrastructure, early adoption of innovative vaccines, and strong public awareness campaigns led by agencies such as the Centers for Disease Control and Prevention (CDC) and the WHO Global Influenza Surveillance and Response System (GISRS).

Regional Insights

North America remains the leading region, supported by high influenza incidence and strong vaccine adoption rates. The U.S. alone recorded approximately 37.2 million influenza cases in 2021, reinforcing the need for annual immunization programs.

Europe follows as the second-largest market, supported by government procurement initiatives and large-scale vaccination programs. The region accounted for USD 2.45 billion in 2025 and is expected to reach USD 2.63 billion in 2026. Asia Pacific, on the other hand, is emerging as the fastest-growing region due to expanding healthcare access, large population base, and increasing government vaccination campaigns, particularly in China and India.

Market Drivers

A key growth driver is increasing government support for immunization programs. Organizations such as the CDC, WHO, and national health ministries are actively promoting vaccination through public awareness campaigns and free immunization drives. For example, initiatives like "Help Them Fight Flu" have significantly improved vaccination coverage among children and high-risk populations.

Another major driver is rising research and development investment. Pharmaceutical companies are focusing on next-generation vaccines, including mRNA-based and combination vaccines that target both influenza and COVID-19. In 2021, researchers at Duke University developed an experimental mRNA-based combination vaccine targeting both viruses, highlighting future innovation potential.

Industry Developments and Key Companies

The influenza vaccine market is highly competitive, with major pharmaceutical players investing in manufacturing expansion and advanced vaccine platforms.

Key industry participants include:

• Sanofi, a global leader in influenza vaccines, strengthened its position through approvals of Fluzone High-Dose Quadrivalent and Flublok Quadrivalent for the 2022-2023 flu season.
• GlaxoSmithKline plc plays a significant role in European vaccine supply agreements and large-scale production initiatives.
• AstraZeneca continues to contribute through its flu vaccine innovations, including nasal spray vaccine technologies.
• CSL Limited is investing heavily in R&D facilities and next-generation mRNA-based influenza vaccines.
• SINOVAC expanded global vaccine production capabilities through international investments.
• Abbott and Viatris Inc. continue to support global distribution networks.
• BIKEN Co., Ltd. contributes significantly to influenza vaccine development in Japan.

Market Segmentation Trends

Quadrivalent vaccines dominate the market due to broader protection against multiple influenza strains, accounting for the largest share in 2025. Inactivated vaccines also lead the segment with over 92% share in 2026 due to their safety profile and wide regulatory acceptance.

By age group, adult vaccination holds a significant share due to high-risk elderly populations, while pediatric vaccination is expected to grow rapidly due to increasing immunization coverage in developing countries.

Conclusion

Between 2025 and 2034, the influenza vaccine market is expected to experience strong expansion driven by rising disease prevalence, technological advancements in vaccine development, and increasing global immunization efforts. With the market projected to grow from USD 9.2 billion in 2025 to USD 22.49 billion in 2034, the industry presents significant opportunities for pharmaceutical companies and public health organizations worldwide.

Segmentation By Type

• Inactivated
• Live Attenuated

By Valency

• Quadrivalent
• Trivalent

By Age Group

• Pediatric
• Adults

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Region

• North America (By Type, By Valency, By Age Group, By Distribution Channel, and By Country)
  • U.S. (By Valency)
  • Canada (By Valency)
• Europe (By Type, By Valency, By Age Group, By Distribution Channel, and By Country/Sub-region)
  • U.K. (By Valency)
  • Germany (By Valency)
  • France (By Valency)
  • Italy (By Valency)
  • Spain (By Valency)
  • Scandinavia (By Valency)
  • Rest of Europe (By Valency)
• Asia Pacific (By Type, By Valency, By Age Group, By Distribution Channel, and By Country/Sub-region)
  • Japan (By Valency)
  • Korea (By Valency)
  • China (By Valency)
  • India (By Valency)
  • Australia (By Valency)
  • Rest of Asia Pacific (By Valency)
• Latin America (By Type, By Valency, By Age Group, By Distribution Channel, and By Country/Sub-region)
  • Brazil (By Valency)
  • Mexico (By Valency)
  • Rest of Latin America (By Valency)
• Middle East & Africa (By Type, By Valency, By Age Group, By Distribution Channel, and By Country/Sub-region)
  • GCC (By Valency)
  • South Africa (By Valency)
  • Rest of Middle East & Africa (By Valency)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Snapshot of Influenza Vaccine Rate - For Key Countries, 2025
• 4.2. Annual Disease Burden of Influenza - For Key Countries/ Regions, 2025/2025
• 4.3. New Product Launches, By Key Players
• 4.4. Influenza Vaccination Campaigns/Programs Undertaken by Government
• 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
• 4.6. Pricing Analysis - By Key Brand/Key Players, By Key Countries, 2025/2025
• 4.7. Snapshot of Pipeline Analysis of Influenza Vaccines
• 4.8. Impact of COVID-19 on the Market

5. Global Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Inactivated
  • 5.1.2. Live Attenuated
• 5.2. Market Analysis, Insights and Forecast - By Valency
  • 5.2.1. Quadrivalent
  • 5.2.2. Trivalent
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatric
  • 5.3.2. Adults
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital & Retail Pharmacies
  • 5.4.2. Government Suppliers
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Inactivated
  • 6.1.2. Live Attenuated
• 6.2. Market Analysis, Insights and Forecast - By Valency
  • 6.2.1. Quadrivalent
  • 6.2.2. Trivalent
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatric
  • 6.3.2. Adults
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital & Retail Pharmacies
  • 6.4.2. Government Suppliers
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
    • 6.5.1.1. By Valency
  • 6.5.2. Canada
    • 6.5.2.1. By Valency

7. Europe Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Inactivated
  • 7.1.2. Live Attenuated
• 7.2. Market Analysis, Insights and Forecast - By Valency
  • 7.2.1. Quadrivalent
  • 7.2.2. Trivalent
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatric
  • 7.3.2. Adults
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital & Retail Pharmacies
  • 7.4.2. Government Suppliers
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. U.K.
    • 7.5.1.1. By Valency
  • 7.5.2. Germany
    • 7.5.2.1. By Valency
  • 7.5.3. France
    • 7.5.3.1. By Valency
  • 7.5.4. Italy
    • 7.5.4.1. By Valency
  • 7.5.5. Spain
    • 7.5.5.1. By Valency
  • 7.5.6. Scandinavia
    • 7.5.6.1. By Valency
  • 7.5.7. Rest of Europe
    • 7.5.7.1. By Valency

8. Asia Pacific Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Inactivated
  • 8.1.2. Live Attenuated
• 8.2. Market Analysis, Insights and Forecast - By Valency
  • 8.2.1. Quadrivalent
  • 8.2.2. Trivalent
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatric
  • 8.3.2. Adults
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital & Retail Pharmacies
  • 8.4.2. Government Suppliers
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. Japan
    • 8.5.1.1. By Valency
  • 8.5.2. China
    • 8.5.2.1. By Valency
  • 8.5.3. India
    • 8.5.3.1. By Valency
  • 8.5.4. Australia
    • 8.5.4.1. By Valency
  • 8.5.5. Korea
    • 8.5.5.1. By Valency
  • 8.5.6. Rest of Asia Pacific
    • 8.5.6.1. By Valency

9. Latin America Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Inactivated
  • 9.1.2. Live Attenuated
• 9.2. Market Analysis, Insights and Forecast - By Valency
  • 9.2.1. Quadrivalent
  • 9.2.2. Trivalent
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatric
  • 9.3.2. Adults
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital & Retail Pharmacies
  • 9.4.2. Government Suppliers
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
    • 9.5.1.1. By Valency
  • 9.5.2. Mexico
    • 9.5.2.1. By Valency
  • 9.5.3. Rest of Latin America
    • 9.5.3.1. By Valency

10. Middle East & Africa Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Inactivated
  • 10.1.2. Live Attenuated
• 10.2. Market Analysis, Insights and Forecast - By Valency
  • 10.2.1. Quadrivalent
  • 10.2.2. Trivalent
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatric
  • 10.3.2. Adults
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital & Retail Pharmacies
  • 10.4.2. Government Suppliers
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC Countries
    • 10.5.1.1. By Valency
  • 10.5.2. South Africa
    • 10.5.2.1. By Valency
  • 10.5.3. Rest of Middle East & Africa
    • 10.5.3.1. By Valency

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. AstraZeneca
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. CSL Limited (Seqirus)
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. GlaxoSmithKline plc
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Sanofi
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. SINOVAC
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. BIKEN Co., Ltd.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Abbott
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Viatris Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)